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A B S T R A C T
Cancer stem cells, also known as tumor-initiating cells (TICs), are a population of aggressive and self-renewing
cells that are responsible for the initiation and progression of many cancers, including colorectal carcinoma.
Intratumoral hypoxia, i.e. reduced oxygen supply following uncontrolled proliferation of cancer cells, is thought
to support TIC activity by inducing specific hypoxia-responsive mechanisms that are not yet entirely understood.
Using previously established and fully characterized patient-derived TIC cultures, we could observe increased
sphere and colony formation under hypoxic conditions. Mechanistically, microRNA (miRNA)-profiling experi-
ments allowed us to identify miR-215 as one of the main hypoxia-induced miRNAs in primary colon TICs.
Through stable overexpression of miR-215, followed by a set of functional in vitro and in vivo investigations, miR-
215 was pinpointed as a negative feedback regulator, working against the TIC-promoting effects of hypoxia.
Furthermore, we could single out LGR5, a bona fide marker of non-neoplastic intestinal stem cells, as a down-
stream target of hypoxia/miR-215 signaling. The strong tumor- and TIC-suppressor potential of miR-215 and the
regulatory role of the hypoxia/miR-215/LGR5 axis may thus represent interesting points of attack for the de-
velopment of innovative anti-CSC therapy approaches.
1. Introduction
According to the cancer stem cell (CSC) model, tumorigenic prop-
erties are reserved to a rare subset of cancer cells, displaying extensive
self-renewal behavior [1]. Such tumor-initiating cells (TICs) have first
been described in the context of acute myeloid leukemia [2,3], but their
existence has also been reported in different solid tumor types, in-
cluding breast [4], brain [5], lung [6], and colon [7,8] cancer. Since the
first discovery of colon TICs in 2007, many different isolation strategies
(reviewed in Ref. [9]) and surface markers (reviewed in Refs. [10,11])
have been employed, with varying degrees of success. In particular
leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a
bona fide Wnt target and accepted marker of non-neoplastic intestinal
stem cells [12,13], has gained a lot of attention over the last years [14].
Barker and colleagues could show that APC deletion in LGR5+ stem-
like cells results in the massive formation of fast-developing adenomas,
whereas the same genetic alteration showed much less effect in more
differentiated cells [15]. Moreover, a cell lineage tracing study by
Schepers and colleagues could identify LGR5+ cells as the cellular
origin of colonic neoplastic growth [16]. More recently, LGR5 expres-
sion has also been clearly associated with the initiation of both primary
intestinal cancers and colorectal carcinoma (CRC)-derived liver me-
tastasis [17–19]. Taken together, these studies deliver direct experi-
mental evidence for the existence of stem cell-derived colon TICs.
However, due to extensive plasticity and fast population dynamics, the
functional regulation of colon TICs and the molecular control of LGR5
remain incompletely understood.
It has long been noted that cancer cells closely interact with sur-
rounding non-tumor elements, commonly referred to as the tumor mi-
croenvironment (TME). Maintenance of phenotypic plasticity,
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protection from the immune system, and facilitation of metastatic
spread are features that are strongly promoted by the TME [20]. Besides
cellular elements of the TME, intratumoral hypoxia is recognized as one
of the driving forces of cancer initiation and progression [21]. In this
context, hypoxia-responsive microRNAs (miRNAs) are thought to play
an important role in modulating cancer cell activity [22]. Besides miR-
210, which is commonly accepted as the main hypoxia-responsive
miRNA (HRM) [23] with known implications in colon TIC regulation
[24], many additional HRMs are suspected to fine-tune the molecular
interplay between cancer cells and their microenvironment [22].
In the context of glioma, miR-215 has recently been reported as a
HRM that is post-transcriptionally regulated in a HIF-Drosha-dependent
manner [25]. While displaying oncogenic activity in glioma patients,
miR-215 is a suspected CRC suppressor that is frequently down-
regulated in tumor samples, compared to normal colon biopsies
[26–28]. Besides modulating chemoresistance [29] and inhibiting
proliferation, migration, and invasion [30] of differentiated CRC cells,
miR-215 was also shown to specifically target the (cancer) stemness
regulator BMI1 [31]. On the other hand, the functional effects of miR-
215 on TIC activity as well as a potential link to hypoxia signaling are
less well studied in the context of colon CSCs. In the present study, we
show that miR-215–5p is consistently induced by hypoxia in different
primary colon TIC cultures. Furthermore, we identify LGR5 as a novel
hypoxia/miR-215 downstream target of interest. Most importantly, we
demonstrate that miR-215 has strong tumor- and TIC-suppressor po-
tential, thus acting as a negative feedback regulator of hypoxia-induced
TIC activity. Altogether, our results deliver new insights into the mo-
lecular response of colon TICs to hypoxic conditions and highlight miR-
215 as an interesting point of attack for the development of future TIC-
targeting therapy approaches.
2. Materials and methods
2.1. Patients
Following approval by the Comité National d’Éthique de Recherche
du Luxembourg (Reference 201009/09) and the institutional Ethics
Review Panel (ERP-16-032), written informed consent of all patients
was obtained and tissue samples were collected by the Integrated
Biobank of Luxembourg (IBBL), as previously reported [32].
2.2. Cell culture
Primary spheroid cultures (SCs) T6, T18, T20, and T51 were iso-
lated from fresh CRC patient material, fully characterized, and main-
tained in SC conditions, as described previously [33]. TIC enrichment
was achieved by passaging the SCs at least 5 times before further use in
experiments.
2.3. Viral transductions
SCs with stable miR-215 overexpression were generated by using
ready-to-use lentiviral particles (Biosettia) at a multiplicity of infection
of 3–5. Puromycin was used to select transduced cells and transduction
efficiency was evaluated via fluorescence microscopy and qPCR. The
specificity of the LGR5 antibody was assessed by using primary TIC
cultures with stable knockdown of LGR5 via application of a pool of 3
different target-specific short hairpin (sh) RNA constructs against LGR5
(Santa Cruz sc-62559-V) (at a multiplicity of infection of 3–5), followed
by puromycin selection.
2.4. Sphere and colony formation assays
In vitro self-renewal and 2D colony formation capacity were tested
as previously described [24,33]. Limiting dilution assays, with cell
densities ranging from 1 to 1000, were performed in SC conditions and
evaluated using the extreme limiting dilution analysis (ELDA) software
[34]. 3D colony formation assays were performed using a serum-free
mix of 60% SCM medium [33] and 40% methylcellulose medium, i.e.
MethoCult® H4100 (StemCell Technologies), supplemented with bFGF
(Miltenyi Biotec; 20 ng/mL) and EGF (Biomol; 20 ng/mL). After 14
days, resulting 3D colonies were counted under a microscope.
2.5. In vivo assays
Non-obese diabetic/severe-combined immunodeficient gamma
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (NSG) mice were bred in-house
and experiments were performed according to all applicable laws and
regulations, after receiving approval by the institution's animal ex-
perimentation ethics committee and the veterinarian service of the
Ministry of Agriculture (Permit Number: 14-MDM-02 and 16-MDM-01-
EL). In vivo tumor formation assays and serial transplantations were
performed, as previously described [33]. Extracted xenografts were
dissociated and lyzed and gene, miRNA, and protein expression was
assessed.
2.6. Flow cytometry
The expression of the surface markers CD24 and CD44 was checked
via flow cytometry. The samples were prepared and analyzed, as pre-
viously described [33], using a FACS Canto II device. Dead cells were
stained with 1 μM Sytox blue (Life Technologies) and CD24 FITC, FITC
Mouse IgG2a, κ, CD44 PE-Cy7 and PE-Cy7 Mouse IgG2b, κ (BD Bios-
ciences) were used as primary antibodies and respective isotype con-
trols.
2.7. RNA extraction and real-time qPCR
After collection and dissociation of SCs, patient samples, and xe-
nografts, RNA was extracted and reverse transcription (RT) as well as
real-time qPCRs were performed, as previously described [24]. Briefly,
RNA extraction and RT were done using the miRNeasy Mini Kit
(Qiagen) and the miScript II RT Kit (Qiagen), respectively. Expression
levels were assessed with specific primer pairs (sequences: LGR5 for-
ward 5′-AGC-CAT-GAC-CTT-GGC-CCT-GA-3′ and reverse 5′-GCT-GTG-
GAGeCCCeATC-AAA-GCA-3′, TFF1 forward 5′eCCA-GTG-TGC-AAA-
TAA-GGG-CTG-C-3′ and reverse 5′-AGG-CAG-ATC-CCT-GCA-GAA-GTG-
T-3′, TFF2 forward 5′-AAC-TGC-GGC-TTC-CCT-GGA-ATC-A-3′ and re-
verse 5′-GCC-ACA-GTT-TCT-TCG-GTC-TGA-G-3′, TFF3 forward 5′-TCC-
AGC-TCT-GCT-GAG-GAG-TAC-G-3′ and reverse 5′-ATC-CTG-GAG-TCA-
AAG-CAG-CAG-C-3′) for genes and with miScript Primer Assays
(Qiagen) for miRNAs. Samples with poor melting curves and/or
threshold cycle (Ct) values > 35 were considered as not expressed and
removed from the analysis. Quality control and normalization were
performed with the qBase + software (Biogazelle) using the geometric
mean of multiple reference genes (primer sequences available in Refs.
[24,33]).
2.8. Cell lysis and Western blots
SCs and extracted xenografts were washed with PBS and lyzed in
RIPA buffer (Thermo Fisher) with 1% SDS. After adding 1 x Laemmli
buffer, lysates were processed, blotted and detected, as previously de-
scribed [24]. Primary antibodies used in this study were β-Actin (Mil-
lipore, #MAB1501), STAT5 (Santa Cruz, sc-835), LGR5 (Abcam,
75850), and LGR5 (Miltenyi, 130-104-945).
2.9. mRNA and miRNA microarray analysis
Affymetrix GeneChip™ Human Gene 2.0 ST Array and GeneChip™
miRNA 4.0 Array were used to generate mRNA and miRNA expression
profiles of different primary SCs. Filtering and normalization of
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expression intensities were performed as previously described [33,35].
Hypoxia-responsive genes and miRNAs were identified by setting a false
discovery rate (FDR) < 0.05 and a │log2 fold change│ > 1 as the
cutoff values. For identifying potential miR-215 target genes, less strict
cutoff criteria (i.e. FDR<0.1) were used. Differentially expressed
genes (DEGs) and miRNAs (DEMs) were determined with an empirical
Bayesian approach using the Bioconductor limma R package. Normal-
ized expression values were deposited in the Gene Expression Omnibus
(GEO) and ArrayExpress databases and are available under accession
numbers GSE120422, GSE120424, and E-MTAB-7354.
2.10. Public datasets
GSE49246 [28], GSE39582 [36], GSE41258 [37], and the TCGA
cohort (COAD project) were used to study the expression of miR-215
and LGR5 in publicly available CRC datasets. Expression levels of
matching cancer and healthy colon samples were analyzed with a
paired Student's t-test, whereas unpaired Student's t-tests were used for
datasets with non-matching CRC and normal tissue samples.
2.11. Data analysis
GraphPad Prism5 (GraphPad Software) and R 3.2 were used to
analyze and graphically visualize our results. Student's t-tests were used
to assess differences between two end-point conditions, Chi-square tests
were used to analyze single cell assays, and 2-way ANOVA tests were
used to evaluate in vivo tumor growth over time. Unless otherwise
stated, three independent replicates were performed for each experi-
ment and results are shown as mean ± SD.
3. Results
3.1. Hypoxia promotes TIC properties of primary CRC cultures
Increasing evidence supports the view that intratumoral hypoxia
promotes cancer initiation and progression via different mechanisms,
including metabolic reprogramming, immune evasion, and cancer stem
cell maintenance [21]. In the context of CRC, it has been suggested that
hypoxia promotes an immature gene expression profile [38] and that
reduced oxygen levels press cell line-derived CSC-like cells into forming
undifferentiated colonies [39]. However, despite the identification of
individual hypoxia-responsive TIC regulators, such as DUSP2 [40] or
miR-210 [24], the molecular connections between hypoxia and colon
cancer stemness remain relatively poorly understood. Accordingly, we
set out to study the effects of reduced oxygen levels on CRC patient-
derived CSCs. Our methodology thereby comprised the isolation and in-
depth characterization of primary colon TICs, followed by an in-
vestigation of the functional and molecular effects of hypoxic culture
conditions on our different cultures (Fig. 1A). In addition to the pre-
viously described T6, T18, and T20 [28], we established another stable
TIC culture, i.e. T51, derived from a stage IIIB CRC patient (age/sex:
47/m; MSI). The corresponding T51 spheroid culture (SC) displayed
extensive tumorigenic properties (Fig. 1B) as well as high in vitro
(Supplementary Fig. S1) and in vivo (Fig. 1C) self-renewal capacity,
emphasizing its high TIC potential. Interestingly, T51 showed an in-
creased sphere formation ability under hypoxic conditions (Fig. 1D),
similar to T6, T18, and T20 [24]. Reduced oxygen levels also con-
sistently enhanced the clonogenic capacity of our different TIC cultures,
as demonstrated with a series of 3D colony formation assays (Fig. 1E).
Taken together, our results thus clearly highlight the tumorigenic
properties of CRC patient-derived SCs and demonstrate the TIC-pro-
moting effect of hypoxic conditions.
3.2. miR-215 is upregulated under hypoxic culture conditions
With the aim to decipher the molecular mechanisms that cause the
enhanced TIC potential under hypoxia, we performed gene and miRNA
expression profiling experiments, comparing normoxic and hypoxic SCs
for T6 and T18. As several miRNAs have been identified as important
mediators of the hypoxic response in different cancer types [22], we
primarily focused on the identification of hypoxia-responsive miRNAs
(HRMs) in our two selected TIC cultures. Expression analysis via miRNA
microarray experiments (data available under GEO accession number
GSE120424) allowed us to identify multiple HRMs, both for T6
(Fig. 2A) and T18 (Fig. 2B). Interestingly, three candidate miRNAs,
namely miR-210–3p, miR-3178, and miR-215–5p, were differentially
expressed in both SCs (Fig. 2C). However, as miR-3178 showed a
conflicting expression profile, being upregulated in hypoxic T6
(Fig. 2A) but downregulated in T18 (Fig. 2B), we removed this candi-
date HRM from our analysis. Moreover, as miR-210–3p had already
been the main subject of a previous publication [24], we decided to
focus our attention on miR-215–5p. Importantly, using qPCR analysis,
we were not only able to validate its hypoxia-responsiveness in T6 and
T18, but we could also show that miR-215–5p was upregulated in two
additional primary SCs under hypoxia (Fig. 2D), emphasizing the need
to better understand its regulation and role in colon TICs.
3.3. Tumor suppressor miR-215–5p decreases colon TIC activity
Previous studies have highlighted that miR-215 acts as a tumor
suppressor that is frequently downregulated in CRC [26–28]. Similarly,
using both our own patient cohort as well as publicly available ex-
pression data, we could confirm that miR-215–5p is significantly re-
pressed in CRC samples, compared to matching normal counterparts
(Fig. 3A). To further study the role of this miRNA in primary colon TICs,
we generated several different SCs with stable overexpression of miR-
215, using a lentiviral transduction system (expression control in
Supplementary Fig. S2A). We first looked at the effect of miR-215 on
the expression of accepted colon TIC surface markers. In this context,
CD44+/CD24+ CRC cells are suspected to display increased in vitro
colony formation and in vivo tumor formation potential [41,42].
Strikingly, miR-215 overexpression resulted in a significant depletion of
the CD44+ and CD24+/CD44+ populations in different SCs (Fig. 3B),
hinting at the TIC-suppressive activity of this miRNA. Furthermore, we
could also observe impaired TIC functionality after miR-215 over-
expression, as demonstrated by reduced 2D (Fig. 3C) and 3D (Fig. 3D)
colony formation as well as repressed self-renewal capacity (Fig. 3E).
Moreover, as also in vivo tumor growth was significantly decreased after
miR-215 overexpression (Fig. 3F; overexpression control in
Supplementary Fig. S2B), our results allow us to conclude that this
miRNA acts as a potent tumor- and TIC suppressor in the context of
CRC.
3.4. Identification of hypoxia-responsive miR-215–5p target genes
With the aim of further dissecting the molecular regulation of colon
TICs, we tried to identify common hypoxia- and miR-215-responsive
genes. By leveraging our previously performed microarray experiments
for T6 and T18 SCs, we could identify 502 genes that were significantly
deregulated under hypoxic conditions in both TIC cultures (Fig. 4A,
left). Furthermore, lentiviral transduction of miR-215 in T51 TICs led us
to determine 66 genes that were differentially expressed after miR-215
overexpression (Fig. 4A, right). The intersection of both lists allowed us
to identify 8 genes of interest that were both sensitive to hypoxia and
miR-215-responsive. In this manner, we could observe that trefoil factor
2 (TFF2), a member of the TFF protein family, which is suspected to be
involved in the initiation of different human cancer types [43], was
significantly deregulated under hypoxic conditions, both in T6 and T18
TICs (Fig. 4A). The O2-sensitivity of TFF2 as well as of the other TFF
members, i.e. TFF1 and TFF3, was validated by qPCR (Fig. 4B–D). All
three TFF family members thereby showed a significant upregulation
under hypoxia, which was consistent in all the tested TIC cultures.
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Moreover, we were able to partially block the hypoxia-induced ex-
pression of the three TFFs by using HIF1A short hairpin RNA
(Supplementary Figs. S3A–C; knockdown control in Supplementary Fig.
S2C), further emphasizing the hypoxia-responsiveness of this protein
family. Most interestingly, the well-accepted colon CSC marker LGR5,
known to be essential for CRC initiation and metastatic spreading of the
disease [17–19], was also among the identified candidates (Fig. 4A).
Using a similar approach, we were able to confirm the regulatory link
between O2 and LGR5: although LGR5 did not respond to HIF1A re-
pression (Supplementary Fig. S3D), we could observe a significant
downregulation of both LGR5 gene (Fig. 4E) and protein (Fig. 4F, refer
to Supplementary Fig. S4 for LGR5 antibody specificity) levels under
hypoxic conditions. The fact that LGR5, in contrast to the different
TFFs, did not respond to HIF1A modulation suggests that other hy-
poxia-responsive factors, such as HIF2A or miR-215, might be involved
in the regulation of LGR5.
3.5. The colon TIC marker LGR5 is a hypoxia/miR-215 downstream target
The clinical relevance of LGR5 expression was examined using both
our own CRC patient collection and large publicly available datasets.
For each tested cohort, LGR5 was significantly increased in tumor
Fig. 1. Hypoxia promotes colon TIC expansion. (A) Study overview: Following in vitro and in vivo characterization, primary colon tumor-initiating cell (TIC)
cultures are cultivated under normoxic and hypoxic (1% O2) conditions. Functional effects as well as molecular alterations are analyzed, with a special focus on
hypoxia-responsive miRNAs (HRMs). (B) In vivo tumor growth after injection of different T51 TIC doses. Tumor incidence for each dose is indicated in brackets, data
shown as mean ± SEM. (C) In vivo self-renewal capacity, determined by serial transplantation of T51 TICs. Secondary tumor incidence was assessed, following
injection of different doses of dissociated primary T51 xenografts. (D) Sphere formation assay with 1000 T51 TICs per well, following 7 days of normoxic (N) or
hypoxic (H) conditions. Representative assay of 3 independent experiments, mean ± SD. Scale bar corresponds to 100 μm. (E) 3D colony formation assay with
250 cells per well for different primary TIC cultures, following 14 days of normoxia or hypoxia. Representative assay of at least 3 independent experiments,
mean ± SD. Unpaired Student's t-tests were used to assess the statistical significance for (D) and (E); *p < 0.05 and ***p < 0.001.
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samples, compared to normal colon tissue biopsies (Fig. 5A and
Supplementary Fig. S5A). The expression profile of LGR5 thus showed
an opposite trend, compared to miR-215–5p (Fig. 3A), emphasizing its
suitability as a potential miR-215–5p target gene. On the other hand,
there was no observable difference in TFF gene expression between
normal and cancerous samples (Supplementary Figs. S5B–D). Although
other groups have linked individual TFFs to apoptosis resistance
[44,45] as well as to CRC development and progression [46,47], we
failed to observe such a correlation between TFF expression and CRC
disease occurrence and thus decided to rather focus on LGR5 for the
scope of the present study. Importantly, by using qPCR analysis to
validate our microarray experiments, we could confirm the miR-215-
responsiveness of LGR5 in two additional TIC cultures (Fig. 5B). Stable
miR-215 overexpression under normoxia thereby diminished LGR5
expression, both on gene and on protein level, to a similar extent as
hypoxia (Fig. 5C and D). The clinical relevance of our findings and the
link of miR-215/LGR5 signaling to CRC tumor growth was further
supported by the fact that LGR5 was significantly repressed in our
previously extracted miR-215-overexpressing xenografts (Fig. 5E). We
could thus consistently observe a strong hypoxia-responsiveness of miR-
215 and LGR5 as well as a distinct regulatory connection between both
factors, throughout all our in vitro and in vivo experiments. It is likely
Fig. 2. miR-215-5p expression is induced under hypoxic conditions. Heatmap depicting the median-centered expression intensities of the 10 most significant
differentially expressed miRNAs (DEMs), ranked according to their adjusted p-value, for (A) T6 and (B) T18 TIC cultures, following 72 h of normoxic (N) or hypoxic
(H) conditions, respectively. Normalized log2 expression intensities are available under the GEO accession number GSE120424. (C) Determination of common
hypoxia-responsive DEMs for T6 and T18 TICs. NB: While miR-210–3p and miR-215–5p were commonly upregulated under hypoxia in T6 and T18, miR-3178
showed an opposite expression behavior in both TIC cultures. (D) Relative miR-215–5p expression in different primary TIC cultures, following 72 h of normoxic (N)
or hypoxic (H) conditions. Representative assay of at least 3 independent experiments, mean ± SD. Unpaired Student's t-test was used to assess the statistical
significance for (D); *p < 0.05, **p < 0.01, and ***p < 0.001.
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Fig. 3. Hypoxia-responsive miR-215 displays tumor- and TIC-repressive properties. (A) Relative miR-215–5p expression in matching colorectal cancer (CRC)
samples and normal colon counterparts. Both own (left) and publicly available (right) patient cohorts were used for our analysis, n= 50 and n=40 sample pairs,
respectively; mean ± SD. (B) CD24high and CD44high populations were determined via FACS analysis in T20 and T51 TIC cultures, following lentiviral transduction
of miR-215 or the respective control vector. Data shown as mean ± SD of 4 (for T20) or 3 (for T51) independent experiments. (C) 2D colony formation assay with
250 cells per well for different primary TIC cultures, following lentiviral transduction of miR-215 or the respective control vector. Colonies were counted after 10–14
days. Representative assay of at least 2 independent experiments, mean ± SD. (D) 3D colony formation assay with 400 cells per well for different primary TIC
cultures, following lentiviral transduction of miR-215 or the respective control vector. Colonies were counted after 14 days, following normoxic (N) or hypoxic (H)
culture conditions. Representative assay of at least 3 independent experiments, mean ± SD. (E) Single cell assay for different primary TIC cultures, following
lentiviral transduction of miR-215 or the respective control vector. Spheres were counted after 10–14 days of hypoxia. Representative assay of at least 3 independent
experiments, mean with 95% confidence interval. (F) In vivo tumor growth after injection of 100 T20 TICs, following lentiviral transduction of miR-215 or the
respective control vector. Data shown as mean ± SEM. Statistical significance was assessed with a paired Student's t-test for (A), an unpaired Student's t-test for
(B–C), a 2-way ANOVA test for (D) and (F), and a Chi-square test for (E); ns – not significant, *p < 0.05, **p < 0.01, and ***p < 0.001.
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Fig. 4. Identification and validation of hypoxia-responsive genes of interest. (A) Determination of genes that are both hypoxia-responsive and potential miR-
215 targets in colon TICs. Intersection of 502 hypoxia-responsive genes that are differentially expressed in T6 and T18 TICs under hypoxia (left circle), and 66 genes
that are differentially expressed after lentiviral transduction of miR-215 in T51 TICs (right circle). Corresponding microarray data is available under accession
numbers E-MTAB-7354 and GSE120422. Relative (B) TFF1, (C) TFF2, (D) TFF3, and (E) LGR5 expression after 7 days of normoxic (N) or hypoxic (H) conditions.
Microarray results for T6 and T18 (left) as well as one representative of at least 2 independent qPCR validation experiments for T6, T18, and T20 (right) are shown;
mean ± SD. (F) LGR5 protein expression (Abcam antibody) in T6 and T18 TICs after 24 h under normoxic (N) or hypoxic (H) culture conditions, respectively.
Representative picture of at least 2 independent Western blot experiments. Statistical significance for (B–E) was assessed with unpaired Student's t-tests; *p < 0.05,
**p < 0.01, and ***p < 0.001.
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that miR-215 represses a transcriptional coactivator, which could in-
directly cause down-regulation of LGR5, as there are no reported
binding sites for miR-215 at the three prime untranslated region
(3′UTR) of LGR5 (www.targetscan.org). However, future studies are
needed in order to unravel the missing link between miR-215 and
LGR5. Altogether, our results highlight miR-215 as a potent TIC-sup-
pressing HRM and identify the colon CSC marker LGR5 as a hypoxia/
miR-215 downstream target. As all the molecular key players of this
study have known clinical implications in CRC, modulating the hy-
poxia/miR-215/LGR5 axis might open up new avenues for therapeutic
TIC-targeting interventions.
4. Discussion
Numerous research initiatives have focused on the relation between
miRNAs and hypoxia signaling as well as on the regulatory role of
HRMs in the context of cancer progression [22]. For instance, miR-424
was shown to inhibit the hydroxylation of HIF1A isoforms, thereby
stabilizing HIF proteins in endothelial cells [48]. Similarly, miR-31 is
known to increase the expression of HIF1A via downregulation of the
HIF-repressor FIH-1 in head and neck carcinoma [49]. On the other
hand, the oncogenic miR-17–92 cluster as well as p53-induced miR-107
were shown to decrease HIF protein levels via repression of the HIF α-
or β-subunit, respectively [50,51]. These results illustrate that, de-
pending on the context, miRNA-mediated upstream regulation of HIFs
can either potentiate or repress the hypoxic response.
Fig. 5. The colon TIC marker LGR5 is a hypoxia/miR-215 downstream target. (A) Relative LGR5 expression in colorectal cancer (CRC) and normal colon
samples. Both our own paired (left) as well as non-matching publicly available (right) patient cohorts were used for the analysis; patient number (n) is indicated for
the respective datasets; mean ± SD. (B) Relative LGR5 expression following lentiviral transduction of miR-215 or the respective control vector. Microarray results
for T51 (left) as well as one representative of at least 2 independent qPCR validation experiments for T6 and T20 (right) are shown; mean ± SD. (C) Relative LGR5
gene and (D) LGR5 protein expression (Miltenyi antibody) in T20 TICs, after 72 h of hypoxia and/or following lentiviral transduction of miR-215 or the respective
control vector. Representative assay of 3 independent experiments; qPCR data shown as mean ± SD. (E) Relative LGR5 expression in extracted xenografts, 45 days
after injection of 100 T20 TICs, previously transduced with miR-215 or the respective control vector; mean ± SD; n=4. Statistical significance was assessed with a
paired Student's t-test for (A, left) and (E), with unpaired Student's t-tests for (A, right) and for (B), and with a 2-way ANOVA test for (C); *p < 0.05, **p < 0.01, and
***p < 0.001.
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Other miRNAs act downstream of HIFs, which entails that their
expression level can be directly or indirectly modified by tumor hy-
poxia. Here again, depending on the molecular context, HRMs can ei-
ther amplify or work against the effects of hypoxia. For instance, miR-
210, the most noted HRM, has been described to act as a negative
feedback mechanism in neural progenitor cells, protecting against hy-
poxia-induced apoptosis [52]. On the other hand, miR-210 was shown
to potentiate the TIC-promoting effects of hypoxia in the context of
colon CSCs [24]. In a similar way, expression and functional impact of
miR-215 also seem to depend on its molecular framework and inter-
action partners: although miR-215 is thought to display oncogenic ac-
tivity in glioma TICs [25], the same miRNA is suspected to act as a
tumor and CSC suppressor in the context of CRC [26–28]. Our own
results thereby extend the findings of Hu et al. and Jones et al., con-
solidating miR-215 as both a HRM and a strong repressor of TIC ac-
tivity. While hypoxia itself promoted the self-renewal capacity of our
CSC cultures, hypoxia-induced miR-215 clearly worked against this
effect, providing negative feedback and acting as a fine-tuning me-
chanism of the hypoxic response.
Most studies agree on the fact that LGR5 marks a population of
cancer cells with increased tumor initiation and progression potential
[15–19]. Reduced LGR5 levels after stable overexpression of miR-215,
as observed here and elsewhere [53], could thus hint at a selective
depletion of tumorigenic cells in the corresponding cultures. However,
a study by Walker and colleagues suggests that inhibition of LGR5 leads
to a rather enhanced proliferative and invasive capacity of CRC cells
[54]. Hence it seems that the functional role of LGR5, while being a
well-established CSC marker, still merits further investigation. Whether
or not the CSC-repressing potential of miR-215 is mediated via inhibi-
tion of LGR5 remains to be determined and will be the subject matter of
future studies. As it stands for now, our findings clearly demonstrate
that LGR5 is a downstream target of hypoxia/miR-215 signaling and,
most importantly, highlight miR-215 as a HRM with strong colon TIC-
suppressing activity, paving the way for the development of novel anti-
CSC treatment strategies.
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